https://www.biospace.com/mrna mRNA en-US Fri, 24 Apr 2026 11:40:22 GMT https://www.biospace.com/press-releases/cmuh-and-partners-unveil-breakthrough-targeted-exosome-platform-for-non-invasive-spinal-cord-injury-repair Fri, 24 Apr 2026 11:40:22 GMT https://www.biospace.com/press-releases/cmuh-and-partners-unveil-breakthrough-targeted-exosome-platform-for-non-invasive-spinal-cord-injury-repair https://www.biospace.com/press-releases/moderna-announces-initiation-of-phase-3-study-of-investigational-mrna-pandemic-influenza-vaccine-candidate Wed, 22 Apr 2026 06:28:59 GMT https://www.biospace.com/press-releases/moderna-announces-initiation-of-phase-3-study-of-investigational-mrna-pandemic-influenza-vaccine-candidate https://www.biospace.com/press-releases/remix-therapeutics-announces-oral-presentation-of-first-in-class-small-molecule-myb-mrna-degrader-rem-422-phase-1-2-aria-trial-results-at-the-2026-american-society-of-clinical-oncology-annual-meeting Wed, 22 Apr 2026 03:16:33 GMT https://www.biospace.com/press-releases/remix-therapeutics-announces-oral-presentation-of-first-in-class-small-molecule-myb-mrna-degrader-rem-422-phase-1-2-aria-trial-results-at-the-2026-american-society-of-clinical-oncology-annual-meeting https://www.biospace.com/press-releases/moderna-receives-european-commission-marketing-authorization-for-mcombriax-modernas-mrna-combination-vaccine-against-influenza-and-covid-19 Tue, 21 Apr 2026 15:11:33 GMT https://www.biospace.com/press-releases/moderna-receives-european-commission-marketing-authorization-for-mcombriax-modernas-mrna-combination-vaccine-against-influenza-and-covid-19 https://www.biospace.com/press-releases/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology Tue, 21 Apr 2026 12:22:43 GMT https://www.biospace.com/press-releases/flagship-pioneering-launches-serif-biomedicines-to-establish-modified-dna-as-a-new-biotechnology https://www.biospace.com/press-releases/aacr-2026-oral-presentation-abogen-presents-preliminary-results-of-abo2203-mrna-encoded-cd3-cd19-tce-from-first-in-human-clinical-study-in-r-r-b-nhl Mon, 20 Apr 2026 15:20:30 GMT https://www.biospace.com/press-releases/aacr-2026-oral-presentation-abogen-presents-preliminary-results-of-abo2203-mrna-encoded-cd3-cd19-tce-from-first-in-human-clinical-study-in-r-r-b-nhl https://www.biospace.com/press-releases/eclipsebio-launches-ecompass-an-ai-enabled-lab-in-the-loop-platform-for-rna-therapeutic-development Mon, 20 Apr 2026 15:16:03 GMT https://www.biospace.com/press-releases/eclipsebio-launches-ecompass-an-ai-enabled-lab-in-the-loop-platform-for-rna-therapeutic-development https://www.biospace.com/press-releases/genflow-biosciences-plc-announces-strategic-technology-collaboration Mon, 20 Apr 2026 07:56:57 GMT https://www.biospace.com/press-releases/genflow-biosciences-plc-announces-strategic-technology-collaboration https://www.biospace.com/press-releases/moderna-to-present-phase-1-2-data-on-its-investigational-cancer-antigen-therapy-mrna-4359-as-first-line-therapy-in-combination-with-pembrolizumab-in-locally-advanced-or-metastatic-melanoma-at-the-2026-aacr-annual-meeting Mon, 20 Apr 2026 06:31:56 GMT https://www.biospace.com/press-releases/moderna-to-present-phase-1-2-data-on-its-investigational-cancer-antigen-therapy-mrna-4359-as-first-line-therapy-in-combination-with-pembrolizumab-in-locally-advanced-or-metastatic-melanoma-at-the-2026-aacr-annual-meeting https://www.biospace.com/press-releases/create-medicines-to-showcase-multi-immune-in-vivo-car-t-car-nk-and-all-rna-retrot-platform-at-aacr-2026 Mon, 20 Apr 2026 02:04:55 GMT https://www.biospace.com/press-releases/create-medicines-to-showcase-multi-immune-in-vivo-car-t-car-nk-and-all-rna-retrot-platform-at-aacr-2026 https://www.biospace.com/press-releases/storm-therapeutics-secures-56-million-series-c-financing-and-doses-first-patient-in-phase-2-sarcoma-trial-of-stc-15 Thu, 16 Apr 2026 10:17:33 GMT https://www.biospace.com/press-releases/storm-therapeutics-secures-56-million-series-c-financing-and-doses-first-patient-in-phase-2-sarcoma-trial-of-stc-15 https://www.biospace.com/press-releases/alida-biosciences-launches-epiplex-tri-mod-service-for-simultaneous-profiling-of-three-key-mrna-modifications Thu, 16 Apr 2026 04:53:23 GMT https://www.biospace.com/press-releases/alida-biosciences-launches-epiplex-tri-mod-service-for-simultaneous-profiling-of-three-key-mrna-modifications https://www.biospace.com/press-releases/wobble-genomics-to-present-novel-mrna-sequencing-research-at-aacr-2026 Wed, 15 Apr 2026 13:46:15 GMT https://www.biospace.com/press-releases/wobble-genomics-to-present-novel-mrna-sequencing-research-at-aacr-2026 https://www.biospace.com/press-releases/sanofi-becomes-market-authorization-holder-for-nuvaxovid-in-canada-expanding-covid-19-vaccine-choices-for-canadians Fri, 10 Apr 2026 06:26:56 GMT https://www.biospace.com/press-releases/sanofi-becomes-market-authorization-holder-for-nuvaxovid-in-canada-expanding-covid-19-vaccine-choices-for-canadians https://www.biospace.com/press-releases/moderna-to-present-revaccination-data-for-its-investigational-seasonal-influenza-vaccine-and-for-mresvia-at-escmid-2026 Tue, 07 Apr 2026 07:11:54 GMT https://www.biospace.com/press-releases/moderna-to-present-revaccination-data-for-its-investigational-seasonal-influenza-vaccine-and-for-mresvia-at-escmid-2026 https://www.biospace.com/press-releases/4basebio-announces-major-expansion-to-support-the-growing-demand-of-ruo-and-hq-synthetic-dna-with-lease-of-an-innovation-hub-and-manufacturing-facility-in-cambridge-uk Tue, 31 Mar 2026 12:30:47 GMT https://www.biospace.com/press-releases/4basebio-announces-major-expansion-to-support-the-growing-demand-of-ruo-and-hq-synthetic-dna-with-lease-of-an-innovation-hub-and-manufacturing-facility-in-cambridge-uk https://www.biospace.com/press-releases/cancervax-reports-successful-initial-mouse-study-with-breakthrough-results Tue, 31 Mar 2026 10:43:21 GMT https://www.biospace.com/press-releases/cancervax-reports-successful-initial-mouse-study-with-breakthrough-results https://www.biospace.com/press-releases/sarepta-announces-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1 Wed, 25 Mar 2026 14:52:58 GMT https://www.biospace.com/press-releases/sarepta-announces-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1 https://www.biospace.com/press-releases/remix-therapeutics-granted-fda-fast-track-designation-for-rem-422-for-the-treatment-of-recurrent-metastatic-or-unresectable-adenoid-cystic-carcinoma Thu, 19 Mar 2026 12:23:25 GMT https://www.biospace.com/press-releases/remix-therapeutics-granted-fda-fast-track-designation-for-rem-422-for-the-treatment-of-recurrent-metastatic-or-unresectable-adenoid-cystic-carcinoma https://www.biospace.com/press-releases/aro-biotherapeutics-reports-positive-phase-1b-topline-results-for-abx1100-a-muscle-targeted-gys1-sirna-in-patients-with-late-onset-pompe-disease-lopd Wed, 18 Mar 2026 01:16:58 GMT https://www.biospace.com/press-releases/aro-biotherapeutics-reports-positive-phase-1b-topline-results-for-abx1100-a-muscle-targeted-gys1-sirna-in-patients-with-late-onset-pompe-disease-lopd